Portal de Periódicos da CAPES

Gadobenate dimeglumine‐enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation

2001; Wiley; Volume: 14; Issue: 5 Linguagem: Inglês

10.1002/jmri.1216

1522-2586

Günther Schneider, Miles A. Kirchin, Gianpaolo Pirovano, Cesare Colosimo, J. Ruscalleda, M. Korves, Isabella Salerio, Anna La Noce, Alberto Spinazzi,

Medical Imaging Techniques and Applications

Abstract Seventy‐four patients with one to eight proven intraaxial metastatic lesions to the brain received a total gadobenate dimeglumine dose of 0.3 mmol/kg of body weight, administered as three sequential bolus injections of 0.1 mmol/kg, at 10‐minute intervals over a 20‐minute period. Quantitative and qualitative assessments of efficacy were performed after each injection and a full evaluation of safety was conducted. Cumulative dosing produced significant ( P < 0.01) dose‐related increases in lesion‐to‐brain (L/B) ratio and lesion signal intensity (SI) enhancement. Two independent, blinded assessors noted additional lesions, compared to unenhanced images in 31% and 33%, 49% and 42%, and 50% and 48% of patients after each cumulative dose, respectively. Significantly more lesions were noted after the first injection, compared to unenhanced images ( P = 0.002 and P < 0.001; assessors 1 and 2, respectively), and after a second injection, compared to the first ( P < 0.001 and P = 0.039; assessors 1 and 2, respectively). Neither assessor noted significantly more lesions after the third injection. For patients with just one lesion observed on unenhanced T1‐ and T2‐weighted images, additional lesions were noted by assessors 1 and 2 for 27% and 26%, 48% and 35%, and 42% and 41% of patients, respectively, following each injection. Contemporaneously, diagnostic confidence was increased and lesion conspicuity improved over unenhanced magnetic resonance imaging (MRI). For patients with one lesion observed after 0.1 mmol/kg of gadobenate dimeglumine, additional lesions were noted for 24% and 17% of patients (assessors 1 and 2, respectively) following a second 0.1 mmol/kg injection. Only assessor 2 noted additional lesions following the third 0.1 mmol/kg injection. The findings of on‐site investigators concurred with those of the two off‐site assessors. No safety concerns were apparent. J. Magn. Reson. Imaging 2001;14:525–539. © 2001 Wiley‐Liss, Inc.